Theriva Biologics Stock Performance
| TOVX Stock | USD 1.28 0.02 1.59% |
The entity has a beta of 1.56, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Theriva Biologics will likely underperform. At this point, Theriva Biologics has a negative expected return of -0.61%. Please make sure to validate Theriva Biologics' kurtosis, market facilitation index, and the relationship between the value at risk and rate of daily change , to decide if Theriva Biologics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Theriva Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:25 | Dividend Date 2018-08-13 | Last Split Date 2024-08-26 |
1 | On Healthcare, Trump and Harris Actually Have Some Similarities | 09/12/2024 |
2 | SCAN, Astrana Launch MA Plan Tailored to Asian Older Adults | 10/02/2024 |
3 | Suki Secures 70M To Expand AI Offerings | 10/14/2024 |
4 | MedCity FemFwd How Doulas Can Improve Maternal Health Outcomes | 10/29/2024 |
5 | Digital Hypertension Solutions Are Everywhere, But Which Truly Improve Outcomes and Lower Costs | 10/31/2024 |
6 | 4 Areas Within Mental Health Care that Give Executives Hope | 11/07/2024 |
7 | Theriva Biologics presenta los aspectos operativos ms destacados y los resultados financieros del tercer trimestre de 2024 | 11/13/2024 |
8 | Video What Would Happen If Prior Authorization Went Away | 11/14/2024 |
9 | Evvy Introduces Treatments for Common Vaginal Symptoms | 11/18/2024 |
10 | SYN Prop E Tech SA Q3 2024 Earnings Call Highlights Strategic Capital Moves and ... | 11/19/2024 |
11 | Twin Brothers Launch Seen Health with 22M to Provide Culturally-Focused Care for Seniors | 11/22/2024 |
| Begin Period Cash Flow | 41.9 M |
Theriva |
Theriva Biologics Relative Risk vs. Return Landscape
If you would invest 330.00 in Theriva Biologics on August 26, 2024 and sell it today you would lose (202.00) from holding Theriva Biologics or give up 61.21% of portfolio value over 90 days. Theriva Biologics is currently does not generate positive expected returns and assumes 13.339% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Theriva, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Theriva Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Theriva Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Theriva Biologics, and traders can use it to determine the average amount a Theriva Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0457
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TOVX |
Estimated Market Risk
| 13.34 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.61 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Theriva Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Theriva Biologics by adding Theriva Biologics to a well-diversified portfolio.
Theriva Biologics Fundamentals Growth
Theriva Stock prices reflect investors' perceptions of the future prospects and financial health of Theriva Biologics, and Theriva Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Theriva Stock performance.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (11.11 M) | ||||
| Shares Outstanding | 2.78 M | ||||
| Price To Book | 0.14 X | ||||
| EBITDA | (19.85 M) | ||||
| Net Income | (18.35 M) | ||||
| Cash And Equivalents | 52.27 M | ||||
| Cash Per Share | 3.30 X | ||||
| Total Debt | 2.15 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 4.14 X | ||||
| Book Value Per Share | 53.89 X | ||||
| Cash Flow From Operations | (19 M) | ||||
| Earnings Per Share | (32.59) X | ||||
| Market Capitalization | 3.56 M | ||||
| Total Asset | 55.22 M | ||||
| Retained Earnings | (309.32 M) | ||||
| Working Capital | 20.66 M | ||||
About Theriva Biologics Performance
Evaluating Theriva Biologics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Theriva Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Theriva Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (361.80) | (343.71) | |
| Return On Tangible Assets | (0.62) | (0.65) | |
| Return On Capital Employed | (0.44) | (0.42) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (0.46) | (0.49) |
Things to note about Theriva Biologics performance evaluation
Checking the ongoing alerts about Theriva Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Theriva Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Theriva Biologics generated a negative expected return over the last 90 days | |
| Theriva Biologics has high historical volatility and very poor performance | |
| Theriva Biologics may become a speculative penny stock | |
| Theriva Biologics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (18.35 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Theriva Biologics currently holds about 52.27 M in cash with (19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.3, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Theriva Biologics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from medcitynews.com: Twin Brothers Launch Seen Health with 22M to Provide Culturally-Focused Care for Seniors |
- Analyzing Theriva Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Theriva Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Theriva Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Theriva Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Theriva Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Theriva Biologics' stock. These opinions can provide insight into Theriva Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.